Nothing Special   »   [go: up one dir, main page]

ES2112431T3 - Procedimiento para el tratamiento de un trastorno mediado por lfa-1. - Google Patents

Procedimiento para el tratamiento de un trastorno mediado por lfa-1.

Info

Publication number
ES2112431T3
ES2112431T3 ES93920241T ES93920241T ES2112431T3 ES 2112431 T3 ES2112431 T3 ES 2112431T3 ES 93920241 T ES93920241 T ES 93920241T ES 93920241 T ES93920241 T ES 93920241T ES 2112431 T3 ES2112431 T3 ES 2112431T3
Authority
ES
Spain
Prior art keywords
lfa
procedure
treatment
mediated disorder
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93920241T
Other languages
English (en)
Inventor
Paula M Jardieu
Bruce Montgomery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2112431T3 publication Critical patent/ES2112431T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Processing Of Solid Wastes (AREA)

Abstract

SE PREVE UN METODO PARA ADMINISTRAR A UN MAMIFERO QUE SUFRE UNA ENFERMEDAD PROVOCADA POR LFA - 1 O QUE CORRE EL RIESGO DE ELLA, UNA DOSIS INICIAL DE UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE ANTAGONISTA LFA - 1, SEGUIDA POR UNAS SUCESIVAS DOSIS INTERMITENTES DE UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE ANTAGONISTA DE LFA - 1 QUE ES MENOR QUE 100 %, CALCULADO SOBRE LA BASE DIARIA DE LA DOSIS INICIAL DE ANTAGONISTA.
ES93920241T 1992-08-21 1993-08-20 Procedimiento para el tratamiento de un trastorno mediado por lfa-1. Expired - Lifetime ES2112431T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93326992A 1992-08-21 1992-08-21

Publications (1)

Publication Number Publication Date
ES2112431T3 true ES2112431T3 (es) 1998-04-01

Family

ID=25463656

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93920241T Expired - Lifetime ES2112431T3 (es) 1992-08-21 1993-08-20 Procedimiento para el tratamiento de un trastorno mediado por lfa-1.

Country Status (14)

Country Link
US (4) US5622700A (es)
EP (1) EP0656789B1 (es)
JP (1) JPH08500826A (es)
AT (1) ATE161192T1 (es)
AU (1) AU687755B2 (es)
CA (1) CA2140933A1 (es)
DE (1) DE69315847T2 (es)
DK (1) DK0656789T3 (es)
ES (1) ES2112431T3 (es)
GR (1) GR3026344T3 (es)
IL (1) IL106756A (es)
MX (1) MX9305070A (es)
WO (1) WO1994004188A1 (es)
ZA (1) ZA936128B (es)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2112431T3 (es) * 1992-08-21 1998-04-01 Genentech Inc Procedimiento para el tratamiento de un trastorno mediado por lfa-1.
FR2700471B1 (fr) * 1993-01-21 1995-04-07 Pasteur Merieux Serums Vacc Utilisation d'anticorps monoclonaux anti-LFA-1 pour la préparation d'un médicament destiné à prévenir le rejet des greffes d'organes solides et médicaments obtenus.
US6884590B1 (en) 1994-02-11 2005-04-26 Cedars-Sinai Medical Center Methods of screening for ulcerative colitis and crohn's disease
US5681699A (en) * 1994-02-11 1997-10-28 Cedars-Sinai Medical Center Methods of diagnosing ulcerative colitis and Crohn's disease
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US20020127201A1 (en) * 1994-07-01 2002-09-12 Dana-Farber Cancer Institute. Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain
EP0831907A4 (en) * 1995-06-06 2005-05-04 D Allen Allen METHOD FOR TREATING MOLLUSCUM CONTAGIOSUM AS A RESULT OF HIV INFECTION
US20040197326A1 (en) * 1995-07-27 2004-10-07 Genentech, Inc. Method for treatment of allergic asthma
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
AU5140196A (en) * 1996-03-29 1997-10-22 Universite Laval Method of restoring a functional protein in a tissue by cell transplantation
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US7122636B1 (en) * 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
FR2763072B1 (fr) * 1997-05-12 1999-11-05 Pasteur Merieux Serums Vacc Utilisation d'un anticorps monoclonal anti-lfa1 en transplantation renale
NZ500974A (en) * 1997-05-17 2001-06-29 Biogen Inc Use of a CD40:CD154 binding interruptor to prevent counter adaptive immune responses in graft rejection
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
WO2000029431A1 (en) * 1998-11-17 2000-05-25 Tanox, Inc. Bispecific molecules cross-linking itim and itam for therapy
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
US6652855B1 (en) * 1999-03-19 2003-11-25 Genentech, Inc. Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
US20010031260A1 (en) * 1999-12-14 2001-10-18 Genentech, Inc. Treatment method
AU2001230920A1 (en) * 2000-01-14 2001-07-24 Genentech Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
EP1267926A2 (en) 2000-03-17 2003-01-02 Millennium Pharmaceuticals, Inc. Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2
DE60140457D1 (de) 2000-09-01 2009-12-24 Blood Res Center Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung
WO2003000863A2 (en) 2001-06-22 2003-01-03 Pioneer Hi-Bred International, Inc. Defensin polynucleotides and methods of use
EP1472275B1 (en) 2002-02-05 2008-12-17 Genentech, Inc. Protein purification
WO2003102132A2 (en) 2002-04-26 2003-12-11 Genetech, Inc. Non-affinity purification of proteins
ES2575547T3 (es) 2003-02-01 2016-06-29 Tanox, Inc. Anticuerpos anti-IgE de humano de alta afinidad
US7834147B2 (en) 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
JP4599355B2 (ja) 2003-07-28 2010-12-15 ジェネンテック， インコーポレイテッド プロテインａアフィニティークロマトグラフィーの間のプロテインａの浸出の低減
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
WO2005051295A2 (en) 2003-11-21 2005-06-09 Anp Technologies, Inc. Asymmetrically branched polymer conjugates and microarray assays
JP2007532681A (ja) * 2004-04-16 2007-11-15 ジェネンテック・インコーポレーテッド Ｂ細胞の枯渇を増大させる方法
MXPA06014354A (es) * 2004-06-09 2007-02-19 Genentech Inc Metodo para tratar granuloma anular o sarcoide.
ZA200701783B (en) * 2004-09-02 2009-10-28 Genentech Inc Anti-Fc-gamma RIIB receptor antibody and uses therefor
US7655229B2 (en) * 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) * 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DE102004059357B8 (de) * 2004-12-03 2009-12-03 Universität Leipzig Antikörper, welcher die Interaktion von humanem Thy-1 und dessen Liganden blockiert, sowie dessen Verwendung
DE602006019709D1 (es) 2005-05-02 2011-03-03 Anp Technologies Inc
CA2985444C (en) 2005-05-17 2019-03-12 Sarcode Bioscience Inc. Compositions and methods for treatment of eye disorders
US20080279848A1 (en) * 2006-03-16 2008-11-13 Genentech, Inc. Methods of treating lupus using CD4 antibodies
KR20080112300A (ko) * 2006-03-16 2008-12-24 제넨테크, 인크. Ｃｄ4 항체를 사용하여 루푸스를 치료하는 방법
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
WO2008011081A2 (en) 2006-07-19 2008-01-24 The Trustees Of The University Of Pennsylvania Wsx-1/p28 as a target for anti-inflammatory responses
PL2097455T3 (pl) 2006-11-02 2015-04-30 Genentech Inc Humanizowane przeciwciała przeciw czynnikowi D
US8362217B2 (en) * 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
WO2008079280A1 (en) * 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
ES2426158T3 (es) 2007-01-22 2013-10-21 Genentech, Inc. Precipitación con polielectrolito y purificación de anticuerpos
EP1995309A1 (en) * 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
KR101643514B1 (ko) 2007-07-09 2016-07-27 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
US20090155176A1 (en) * 2007-10-19 2009-06-18 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
DK2565206T3 (en) 2007-10-30 2016-06-06 Genentech Inc Antibody Purification by cation exchange chromatography
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
WO2009128932A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Delivery of lfa-1 antagonists to the gastrointestinal system
WO2009128934A1 (en) 2008-04-15 2009-10-22 Sarcode Corporation Topical lfa-1 antagonists for use in localized treatment of immune related disorders
JP2011518155A (ja) * 2008-04-15 2011-06-23 サーコード コーポレイション 免疫関連障害の局所治療に使用するためのエアゾール化ｌｆａ−１アンタゴニスト
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US8999702B2 (en) * 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
AR077718A1 (es) * 2008-07-15 2011-09-21 Genentech Inc Metodos para tratar enfermedades autoinmunes usando anticuerpos anti cd4. formulacion farmaceutica
LT2848625T (lt) 2008-08-14 2019-10-10 Genentech, Inc. Priemaišų pašalinimo būdai, panaudojant reziduojančio baltymo pakeitimą jonų mainų membraninės chromatografijos pagalba
KR20110076918A (ko) 2008-09-10 2011-07-06 제넨테크, 인크. 단백질의 산화성 분해를 방지하기 위한 조성물 및 방법
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
WO2010074702A1 (en) 2008-12-16 2010-07-01 Millipore Corporation Purification of proteins
ES2749232T3 (es) 2008-12-16 2020-03-19 Emd Millipore Corp Reactor de tanque agitado y procedimiento
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
WO2010099273A1 (en) 2009-02-27 2010-09-02 Genentech, Inc. Methods and compositions for protein labelling
MX2012001742A (es) 2009-08-11 2012-03-21 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
EP3736338A1 (en) 2009-09-01 2020-11-11 F. Hoffmann-La Roche AG Enhanced protein purification through a modified protein a elution
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
EP2531592A1 (en) 2010-02-04 2012-12-12 Vivalis Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
TR201905081T4 (tr) 2010-03-22 2019-05-21 Hoffmann La Roche Protein içeren formülasyonların stabilizasyonu için yararlı bileşimler ve yöntemler.
PL2796467T3 (pl) 2010-03-31 2018-07-31 Boehringer Ingelheim International Gmbh Przeciwciała anty-CD40
EP4450523A2 (en) 2010-04-02 2024-10-23 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2011139718A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
CN107312062B (zh) 2010-05-17 2021-03-16 Emd密理博公司 用于纯化生物分子的刺激响应性聚合物
PL2576580T3 (pl) 2010-05-28 2017-03-31 F.Hoffmann-La Roche Ag Zmniejszenie poziomu mleczanu i zwiększenie wytwarzania polipeptydu przez obniżenie poziomu ekspresji dehydrogenazy mleczanowej i kinazy dehydrogenazy pirogronianowej
SI3586826T1 (sl) 2010-06-24 2021-09-30 F. Hoffmann-La Roche Ag Sestavki in postopki za stabilizacijo formulacij, ki vsebujejo beljakovine
KR20130100125A (ko) 2010-08-13 2013-09-09 제넨테크, 인크. 질환의 치료를 위한, ＩＬ-1β 및 ＩＬ-18에 대한 항체
BR112013003223A2 (pt) 2010-08-23 2016-06-07 Pioneer Hi Bred Int "polinucleotídeo isolado, cassete de expressão, célula hospedeira, micro-organismo, planta ou parte de planta, método de obtenção de uma planta transformada, composição antipatogênica, método para proteger uma planta contra um patógeno ou uso de um polinucleotídeo isolado"
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
LT2635601T (lt) 2010-11-04 2016-10-10 Boehringer Ingelheim International Gmbh Antikūnai prieš il-23
CN103429267B (zh) 2011-01-09 2016-05-04 Anp科技公司 疏水分子诱导的支化聚合物集合体及其用途
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
DK2714733T3 (da) 2011-05-21 2019-05-06 Macrogenics Inc Cd3-bindende molekyler, der er i stand til at binde til human og ikke-human cd3
SG194763A1 (en) 2011-07-08 2013-12-30 Emd Millipore Corp Improved depth filters for disposable biotechnological processes
LT2780373T (lt) 2011-11-16 2019-09-25 Boehringer Ingelheim International Gmbh Anti il-36r antikūnai
CN108892706A (zh) 2011-12-22 2018-11-27 弗·哈夫曼-拉罗切有限公司 使用离子交换膜层析改进下游蛋白质纯化步骤的方法
KR102096678B1 (ko) 2012-03-27 2020-04-02 제넨테크, 인크. 재조합 단백질을 위한 개선된 수확 작업
EA201401204A1 (ru) 2012-05-03 2015-05-29 Бёрингер Ингельхайм Интернациональ Гмбх Антитела к il-23p19
PL2849723T3 (pl) 2012-05-18 2018-10-31 Genentech, Inc. Formulacje o wysokim stężeniu przeciwciał monoklonalnych
EP4406950A2 (en) 2012-07-25 2024-07-31 Bausch + Lomb Ireland Limited Lfa-1 inhibitor and polymorph thereof
WO2014078522A1 (en) 2012-11-14 2014-05-22 Ohio State Innovation Foundation Materials and methods useful for treating glioblastoma
EP2934602B1 (en) 2012-12-19 2019-02-27 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
EP3881828A3 (en) 2013-02-05 2021-10-13 ANP Technologies, Inc. Nanoparticles containing a taxane and their use
JO3529B1 (ar) 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
KR20230109779A (ko) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
AU2015315834B2 (en) 2014-01-31 2019-12-12 Boehringer Ingelheim International Gmbh Novel anti-BAFF antibodies
EA201692109A1 (ru) 2014-05-01 2017-03-31 Дженентек, Инк. Варианты антител к фактору d и их применение
EP3777535A1 (en) 2014-07-09 2021-02-17 F. Hoffmann-La Roche AG Ph adjustment to improve thaw recovery of cell banks
JP2017524359A (ja) 2014-07-24 2017-08-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー
BR112018001907A2 (pt) 2015-09-01 2018-09-25 Boehringer Ingelheim Int uso de anticorpos anti-cd40 para o tratamento de nefrite lúpica
SI3307322T1 (sl) 2015-09-04 2021-08-31 Primatope Therapeutics Inc. Humanizirana protitelesa proti CD40 in njihove uporabe
JP2018536650A (ja) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
KR20180127416A (ko) 2016-03-17 2018-11-28 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
JP2019510517A (ja) 2016-03-29 2019-04-18 ジェルター， インコーポレイテッド 細胞質内体積に対するペリプラズム体積の比率が０．５：１および１０：１の間にあるグラム陰性細菌におけるタンパク質の発現
JP7553241B2 (ja) 2016-12-22 2024-09-18 ジェネンテック， インコーポレイテッド 凍結乾燥ポリペプチドの再構成時間を低減するための方法及び製剤
JP2020512344A (ja) 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
MX2020013885A (es) 2018-06-29 2021-03-09 Boehringer Ingelheim Int Anticuerpos anti-cd40 para su uso en el tratamiento de enfermedades autoinmunes.
EP4368699A3 (en) 2018-07-03 2024-09-11 Bristol-Myers Squibb Company Methods of producing recombinant proteins
EP3864127A1 (en) 2018-10-10 2021-08-18 Boehringer Ingelheim International GmbH Method for membrane gas transfer in high density bioreactor culture
US11730812B2 (en) 2019-03-08 2023-08-22 Boehringer Ingelheim International Gmbh Anti-IL-36R antibody formulations
KR20210145152A (ko) 2019-04-01 2021-12-01 제넨테크, 인크. 단백질-함유 제제들의 안정화를 위한 조성물들 및 방법들
CN113993885A (zh) 2019-04-12 2022-01-28 格尔托公司 重组弹性蛋白及其生产
CN114514311A (zh) 2019-08-01 2022-05-17 百时美施贵宝公司 改进补料分批细胞培养物中蛋白质产量的方法
CA3169967A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Tie2-binding agents and methods of use
EP4213939A1 (en) 2020-09-21 2023-07-26 Boehringer Ingelheim International GmbH Use of anti-cd40 antibodies for treatment of inflammatory conditions
CN116194570A (zh) 2020-09-22 2023-05-30 百时美施贵宝公司 用于产生治疗性蛋白的方法
WO2022170008A2 (en) 2021-02-05 2022-08-11 Boehringer Ingelheim International Gmbh Anti-il1rap antibodies
WO2023015234A1 (en) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292636A (en) * 1986-03-31 1994-03-08 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using soluble T cell surface molecules
US5762933A (en) * 1987-01-05 1998-06-09 Institut National De La Sante Et De La Recherche Medicale Method for preventing and treating graft failure in a human patient using a monoclonal antibody specific for leucocyte functional antigen LFA-1
EP0303692A4 (en) * 1987-02-26 1990-12-05 Dana Farber Cancer Institute Cloning of lfa-1
US5284931A (en) * 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
DE3854536T2 (de) * 1987-05-04 1996-03-07 Dana Farber Cancer Inst Inc Interzellulare Adhäsions-Moleküle und deren Bindungsliganden.
US5538724A (en) * 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5403919A (en) * 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
US4797277A (en) * 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy
US5002869A (en) * 1987-11-02 1991-03-26 Dana-Farber Cancer Institute Monoclonal antibody specific to a novel epitope of the LFA-1 antigen of human T lymphocytes
ATE114972T1 (de) * 1987-11-02 1994-12-15 Baylor College Medicine Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen.
US5395929A (en) * 1987-12-15 1995-03-07 Dana Farber Cancer Institute Isolated nucleic acid encoding the alpha subunit of the human leukocyte adhesion receptor
US5071964A (en) * 1988-05-04 1991-12-10 Dana-Farber Cancer Institute, Inc. Protein micelles
US5147637A (en) * 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
WO1990008187A1 (en) * 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
CA2008368C (en) * 1989-01-24 2003-04-08 Jeffrey Greve Soluble molecule related to but distinct from icam-1
US5235049A (en) * 1989-01-24 1993-08-10 Molecular Therapeutics, Inc. Nucleic acid sequences encoding a soluble molecule (SICAM-1) related to but distinct from ICAM-1
NO900155L (no) * 1989-01-24 1990-07-25 Molecular Therapeutics Inc Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.
EP0462184A4 (en) * 1989-03-09 1992-01-08 Dana Farber Cancer Institute Method of treating viral infections using lfa-1
DK0387668T3 (da) * 1989-03-09 1997-03-03 Blood Res Center Intercellulært adhæsionsmolekyle-2 og dets bindende ligander
GB8912497D0 (en) * 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
CA2033347C (en) * 1989-06-02 2000-02-29 James E. Hildreth Monoclonal antibodies against leukocyte adhesion receptor beta-chain, methods of producing these antibodies and use therefore
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
GB9009549D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
WO1991018011A1 (en) * 1990-05-15 1991-11-28 Swinburne Limited Inhibition of cell adhesion using intercellular adhesion molecule-1-like peptides and/or analogues thereof
EP0546077A1 (en) * 1990-08-27 1993-06-16 Chiron Corporation Cd18 peptide medicaments for the treatment of disease
DE69129460T2 (de) * 1990-08-31 1998-10-15 Boehringer Ingelheim Pharma Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
ES2206447T3 (es) * 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
EP0610298A1 (en) * 1991-10-01 1994-08-17 The General Hospital Corporation Preventing allograft rejection with antibodies to adhesion molecules
US5854070A (en) * 1992-07-16 1998-12-29 Icos Corporation Murine and humanizer 23F2G antibodies and cell lines expressing said antibodies
EP0604647A4 (en) * 1992-07-16 1996-09-25 Icos Corp Alleviation of symptoms associated with inflammatory disease states.
ES2112431T3 (es) * 1992-08-21 1998-04-01 Genentech Inc Procedimiento para el tratamiento de un trastorno mediado por lfa-1.

Also Published As

Publication number Publication date
US20020197248A1 (en) 2002-12-26
MX9305070A (es) 1994-04-29
EP0656789B1 (en) 1997-12-17
WO1994004188A1 (en) 1994-03-03
CA2140933A1 (en) 1994-02-22
ZA936128B (en) 1995-02-20
DE69315847D1 (de) 1998-01-29
AU687755B2 (en) 1998-03-05
JPH08500826A (ja) 1996-01-30
IL106756A0 (en) 1993-12-08
US5622700A (en) 1997-04-22
DE69315847T2 (de) 1998-06-25
DK0656789T3 (da) 1998-08-24
ATE161192T1 (de) 1998-01-15
GR3026344T3 (en) 1998-06-30
AU5083693A (en) 1994-03-15
IL106756A (en) 2006-07-05
EP0656789A1 (en) 1995-06-14
US20050281817A1 (en) 2005-12-22
US20040120960A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
ES2112431T3 (es) Procedimiento para el tratamiento de un trastorno mediado por lfa-1.
ES2187659T3 (es) Tratamiento de la diabetes mellitus de tipo ii con agonistas de amilina.
PT814831E (pt) Medicamentos para o tratamento de doencas autoimunitarias utilizando o interferao tau
FI920601A0 (fi) Tvaofasig anordning foer transdermal dosering av laekemedel.
ES2165990T3 (es) Thip para el tratamiento de trastornos del sueño.
ES2137948T3 (es) Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina.
DE69835823D1 (de) Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus-interferon
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
WO1994027587A3 (en) Sustained antiepileptic therapy
DK0751769T3 (da) Medicinsk behandling under anvendelse af skjoldbruskhormoner
IL208184A0 (en) Glp-1, and methods for treating diabetes
DK0682514T3 (da) Anvendelse af lokalanæstetiske midler til fremstilling af et lægmiddel til behandling af bronchial astma
MX9203554A (es) Un dispositivo osmotico para administrar doxazosin
ES2194025T3 (es) Toxinas botulinicas multiples para tratar trastornos y enfermedades neuromusculares.
DK0863760T3 (da) Anvendelse af forbindelser med antimineralcorticoid virkning over for narkotikafvænning
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
DK241287A (da) Anvendelse af glutamin til fremstilling af et laegemiddel til behandling af kataboliske forstyrrelser
NZ337073A (en) use of an anti CD40L compound to treat a patient with an autoimmune disease or chronic immune system disorder
MA22915A1 (fr) Methodes de traitement de l'osteoporose pour utilisation de faibles doses de phosphonates.
HK1014498A1 (en) Bpi-protein-products for depressed reticuloendothelial system function.
MY104521A (en) Treatment of depression.
IT1293583B1 (it) Uso dell'acido gammaidrossibutirrico per il trattamento delle sindromi demenziali
ATE222768T1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
AU4530796A (en) Treating disorders characterised by excessive cell proliferation with sclareolide
ATE147983T1 (de) Transdermales therapeutisches system mit pentylentetrazol als wirkstoff

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 656789

Country of ref document: ES